Presently, there are more than 10 approved gene therapies / Roots Analysis

Mar 23, 2021

10 likes | 13 Views

Encouraging clinical results across various metabolic, hematological and ophthalmic disorders have inspired research groups across the world to focus their efforts on the development of novel gene editing therapies. In fact, the gene therapy pipeline has evolved significantly over the past few years, with three products being approved in 2019 alone; namely Beperminogene perplasmid (AnGes), ZOLGENSMAu00ae (AveXis) and ZYNTEGLOu2122 (bluebird bio). Further, there are multiple pipeline candidates in mid to late-stage (phase II and above) trials that are anticipated to enter the market over the next 5-10 years. <br><br>To order this 670 page report, which features 190 figures and 340 tables, please visit this - https://www.rootsanalysis.com/reports/view_document/gene-therapies-market/268.html<br>

kevin987

Download Presentation

Presently, there are more than 10 approved gene therapies / Roots Analysis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D